Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board, Notice of Meeting, 87726-87727 [2024-25538]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 87726 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices Form Number: 8725. Abstract: Treasury Decision (TD) 8379 provide rules relating to the manner and method of reporting and paying the nondeductible 50 percent excise tax imposed by section 5881 of the Internal Revenue Code with respect to the receipt of greenmail. The reporting requirements will be used to verify that the excise tax imposed under section 5881 is properly reported and timely paid. Form 8725 is used by persons who receive ‘‘greenmail’’ to compute and pay the excise tax on greenmail imposed under Internal Revenue Code section 5881. IRS uses the information to verify that the correct amount of tax has been reported. Current Actions: There is no change to these existing collection requirements. Type of Review: Extension of a currently approved collection. Affected Public: Individuals and business or other for-profit organizations. Estimated Number of Responses: 12. Estimated Time per Response: 7 hours, 37 minutes. Estimated Total Annual Burden Hours: 92. The following paragraph applies to all of the collections of information covered by this notice: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103. Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. Comments will be of public record. Comments are invited on: (a) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information has practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information. VerDate Sep<11>2014 17:28 Nov 01, 2024 Jkt 265001 Approved: October 30, 2024. Molly J. Stasko, Senior Tax Analyst. [FR Doc. 2024–25606 Filed 11–1–24; 8:45 am] BILLING CODE 4830–01–P U.S.-CHINA ECONOMIC AND SECURITY REVIEW COMMISSION Notice of Open Public Event U.S.-China Economic and Security Review Commission. ACTION: Notice of open public event. AGENCY: Notice is hereby given of the following open public event of the U.S.China Economic and Security Review Commission. The Commission is mandated by Congress to monitor, investigate, and report to Congress annually on ‘‘the national security implications of the bilateral trade and economic relationship between the United States and the People’s Republic of China.’’ Pursuant to this mandate, the Commission will hold a public release of its 2024 Annual Report to Congress in Washington, DC on November 19, 2024. DATES: The release is scheduled for Tuesday, November 19, 2024 at 10:30 a.m. ADDRESSES: This release will be held inperson at or near the U.S. Capitol and adjacent Congressional office buildings (specific building and room number to be announced) and online via live webcast on the Commission’s website at www.uscc.gov. Please check the Commission’s website for an announcement on the specific event location once determined. Instructions on how to view the webcast and submit questions or participate in the question and answer session will also be posted at USCC.gov. Reservations are not required to attend. FOR FURTHER INFORMATION CONTACT: Any member of the public seeking further information concerning the event should contact Jameson Cunningham, 444 North Capitol Street NW, Suite 602, Washington, DC 20001; telephone: 202– 624–1496, or via email at jcunningham@ uscc.gov. Reservations are not required to attend. ADA Accessibility: For questions about the accessibility of the event or to request an accommodation, please contact Jameson Cunningham at 202– 624–1496, or via email at jcunningham@ uscc.gov. Requests for an accommodation should be made as soon as possible, and at least five business days prior to the event. SUPPLEMENTARY INFORMATION: SUMMARY: PO 00000 Frm 00190 Fmt 4703 Sfmt 4703 Topics to Be Discussed: The Commission’s 2024 Annual Report to Congress addresses key findings and recommendations for Congressional action based upon the Commission’s hearings, research, and review of the areas designated by Congress in its mandate, including focused work this year on: a review of economics, trade, security, and foreign affairs developments in China and in the U.S.China relationship in 2024; China’s progress in emerging technologies at the forefront of U.S.-China competition; the risks to consumer product safety posed by Chinese imports; China’s counterintervention capabilities in the IndoPacific region; U.S. strategies to address China’s nonmarket practices and other aspects of intersecting economic and national security challenges associated with China; the Chinese Communist Party’s efforts to prepare Chinese society for a crisis or conflict; and changing relations between China and the Middle East, Taiwan, and Hong Kong. Authority: Congress created the U.S.China Economic and Security Review Commission in 2000 in the National Defense Authorization Act (Pub. L. 106– 398), as amended by division P of the Consolidated Appropriations Resolution, 2003 (Pub. L. 108–7), as amended by Pub. L. 109–108 (November 22, 2005), as amended by Pub. L. 113– 291 (December 19, 2014). Dated: October 28, 2024. Christopher P. Fioravante, Deputy Executive Director, U.S.-China Economic and Security Review Commission. [FR Doc. 2024–25579 Filed 11–1–24; 8:45 am] BILLING CODE 1137–00–P DEPARTMENT OF VETERANS AFFAIRS Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board, Notice of Meeting The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act, 5 U.S.C. ch.10, that a meeting of the Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board will be held January 7, 2025, via WebEx. The meeting will be held between 3 and 5 p.m. EDT. The meeting will be closed to the public from 3:30–5 p.m. EDT for scientific review and the discussion, examination, and reference to the research applications. Discussions will E:\FR\FM\04NON1.SGM 04NON1 lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices involve reference to staff and consultant critiques of research proposals. Discussions will deal with scientific merit of each proposal and qualifications of personnel conducting the studies, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Additionally, premature disclosure of research information could significantly obstruct implementation of proposed agency action regarding the research proposals. As provided by Public Law 92–463 subsection 10(d), and as amended by Public Law 94–409, closing the committee meeting is in accordance with Title 5 U.S.C. 552b(c) (6) and (9)(B). The objective of the Board is to provide for the fair and equitable selection of the most meritorious research projects for support by VA research funds and to offer advice for research program officials on program priorities and policies. The ultimate objective of the Board is to ensure the high quality and mission relevance of VA’s legislatively mandated Biomedical Laboratory and Clinical Science Research and Development programs. Board members advise the Directors of the Biomedical Laboratory and Clinical Sciences Research Services and the Chief Research and Development Officer on the scientific and technical merit, mission relevance, and protection of human subjects of Biomedical Laboratory and Clinical Sciences Research and Development proposals. The Board does not consider grants, contracts, or other forms of extramural research. Members of the public may attend the open portion of the meeting. The time limited agenda does not enable public comments or presentations. To attend the open portion of the meeting (3–3:30 p.m. EDT), the public may join by dialing the phone number 1–404–397– 1596 and entering the meeting number (access code): 2823 274 3705. Public comments accepted during the open portion of the meeting and public stakeholders who want to speak to the committee will be afforded three minutes during the public comment period. These stakeholders must notify the DFO of their intention to speak to the committee. Written public comments must be sent to Michael R. Burgio, Ph.D., Designated Federal Officer, Advisory Committee Management Office, 811 Vermont Avenue NW, Room 4342A, VerDate Sep<11>2014 17:28 Nov 01, 2024 Jkt 265001 Washington, DC 20006, or to Michael.Burgio@va.gov, at least five days before the meeting. The written public comments will be shared with the Board members. The public may not attend the closed portion of the meeting as disclosure of research information could significantly obstruct implementation of proposed agency action regarding the research proposals (per Pub. L. 92–463 subsection 10(d), as amended by Pub. L. 94–409, closing the committee meeting is in accordance with 5 U.S.C. 552b(c) (6) and (9)(B)). Dated: October 29, 2024. LaTonya L. Small, Federal Advisory Committee Management Officer. [FR Doc. 2024–25538 Filed 11–1–24; 8:45 am] BILLING CODE 8320–01–P DEPARTMENT OF VETERANS AFFAIRS Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board, AMENDED, Notice of Meeting The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act, 5 U.S.C. ch.10, that a meeting of the Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board will be held January 7, 2025, via WebEx. The meeting will be held between 3 and 5 p.m. EDT. The meeting will be closed to the public from 3:30–5 p.m. EDT for scientific review and the discussion, examination, and reference to the research applications. Discussions will involve reference to staff and consultant critiques of research proposals. Discussions will deal with scientific merit of each proposal and qualifications of personnel conducting the studies, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Additionally, premature disclosure of research information could significantly obstruct implementation of proposed agency action regarding the research proposals. As provided by Public Law 92–463 subsection 10(d), and as amended by Public Law 94–409, closing the committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B). PO 00000 Frm 00191 Fmt 4703 Sfmt 9990 87727 The objective of the Board is to provide for the fair and equitable selection of the most meritorious research projects for support by VA research funds and to offer advice for research program officials on program priorities and policies. The ultimate objective of the Board is to ensure the high quality and mission relevance of VA’s legislatively mandated Biomedical Laboratory and Clinical Science Research and Development programs. Board members advise the Directors of the Biomedical Laboratory and Clinical Sciences Research Services and the Chief Research and Development Officer on the scientific and technical merit, mission relevance, and protection of human subjects of Biomedical Laboratory and Clinical Sciences Research and Development proposals. The Board does not consider grants, contracts, or other forms of extramural research. Members of the public may attend the open portion of the meeting. The time limited agenda does not enable public comments or presentations. To attend the open portion of the meeting (3–3:30 p.m. EDT), the public may join by dialing the phone number 1–404–397– 1596 and entering the meeting number (access code): 2823 274 3705. These stakeholders must notify the DFO of their intention to speak to the committee. Written public comments must be sent to Michael R. Burgio, Ph.D., Designated Federal Officer, Advisory Committee Management Office, 811 Vermont Avenue NW, Room 4342A, Washington, DC 20006, or to Michael.Burgio@va.gov, at least five days before the meeting. The written public comments will be shared with the Board members. The public may not attend the closed portion of the meeting as disclosure of research information could significantly obstruct implementation of proposed agency action regarding the research proposals (per Pub. L. 92–463 subsection 10(d), as amended by Public Law 94–409, closing the committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B). Dated: October 29, 2024. LaTonya L. Small, Federal Advisory Committee Management Officer. [FR Doc. 2024–25550 Filed 11–1–24; 8:45 am] BILLING CODE 8320–01–P E:\FR\FM\04NON1.SGM 04NON1

Agencies

[Federal Register Volume 89, Number 213 (Monday, November 4, 2024)]
[Notices]
[Pages 87726-87727]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-25538]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF VETERANS AFFAIRS


Joint Biomedical Laboratory Research and Development and Clinical 
Science Research and Development Services Scientific Merit Review 
Board, Notice of Meeting

    The Department of Veterans Affairs (VA) gives notice under the 
Federal Advisory Committee Act, 5 U.S.C. ch.10, that a meeting of the 
Joint Biomedical Laboratory Research and Development and Clinical 
Science Research and Development Services Scientific Merit Review Board 
will be held January 7, 2025, via WebEx. The meeting will be held 
between 3 and 5 p.m. EDT. The meeting will be closed to the public from 
3:30-5 p.m. EDT for scientific review and the discussion, examination, 
and reference to the research applications. Discussions will

[[Page 87727]]

involve reference to staff and consultant critiques of research 
proposals. Discussions will deal with scientific merit of each proposal 
and qualifications of personnel conducting the studies, the disclosure 
of which would constitute a clearly unwarranted invasion of personal 
privacy. Additionally, premature disclosure of research information 
could significantly obstruct implementation of proposed agency action 
regarding the research proposals. As provided by Public Law 92-463 
subsection 10(d), and as amended by Public Law 94-409, closing the 
committee meeting is in accordance with Title 5 U.S.C. 552b(c) (6) and 
(9)(B).
    The objective of the Board is to provide for the fair and equitable 
selection of the most meritorious research projects for support by VA 
research funds and to offer advice for research program officials on 
program priorities and policies. The ultimate objective of the Board is 
to ensure the high quality and mission relevance of VA's legislatively 
mandated Biomedical Laboratory and Clinical Science Research and 
Development programs.
    Board members advise the Directors of the Biomedical Laboratory and 
Clinical Sciences Research Services and the Chief Research and 
Development Officer on the scientific and technical merit, mission 
relevance, and protection of human subjects of Biomedical Laboratory 
and Clinical Sciences Research and Development proposals. The Board 
does not consider grants, contracts, or other forms of extramural 
research.
    Members of the public may attend the open portion of the meeting. 
The time limited agenda does not enable public comments or 
presentations. To attend the open portion of the meeting (3-3:30 p.m. 
EDT), the public may join by dialing the phone number 1-404-397-1596 
and entering the meeting number (access code): 2823 274 3705. Public 
comments accepted during the open portion of the meeting and public 
stakeholders who want to speak to the committee will be afforded three 
minutes during the public comment period. These stakeholders must 
notify the DFO of their intention to speak to the committee.
    Written public comments must be sent to Michael R. Burgio, Ph.D., 
Designated Federal Officer, Advisory Committee Management Office, 811 
Vermont Avenue NW, Room 4342A, Washington, DC 20006, or to 
[email protected], at least five days before the meeting. The 
written public comments will be shared with the Board members. The 
public may not attend the closed portion of the meeting as disclosure 
of research information could significantly obstruct implementation of 
proposed agency action regarding the research proposals (per Pub. L. 
92-463 subsection 10(d), as amended by Pub. L. 94-409, closing the 
committee meeting is in accordance with 5 U.S.C. 552b(c) (6) and 
(9)(B)).

    Dated: October 29, 2024.
LaTonya L. Small,
Federal Advisory Committee Management Officer.
[FR Doc. 2024-25538 Filed 11-1-24; 8:45 am]
BILLING CODE 8320-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.